Drug Search Results

Galunisertib

Alternative Names: galunisertib, ly2157299
Latest Update: 2024-11-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TGFb Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Galunisertib

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Adenocarcinoma|Colorectal Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
15-050A	P2	Active, not recruiting	Colorectal Cancer\|Adenocarcinoma	2025-12-01
2016-002349-50	P2	Active, not recruiting	Colorectal Cancer	2019-03-29

Recent News Events

Date	Type	Title
05/13/2024	PubMed	Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta.
05/05/2024	PubMed	CLIP170 inhibits the metastasis and EMT of papillary thyroid cancer through the TGF-β pathway.
04/28/2024	PubMed	Injectable platelet-rich fibrin promotes proliferation and trichogenic inductivity of dermal papilla cells through activating TGF-β/Smad signaling pathway.
09/06/2023	News Article	Transforming Growth Factor Beta 1 Market (New Insights Report) report is segmented into several key countries, with market size, growth rate, import and export in these countries from 2023 to 2030
11/13/2020	News Article	twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates
04/03/2020	News Article	TGF Beta Receptor Type 1 - 2020 Pipeline Review, H1 - ResearchAndMarkets.com
05/15/2019	News Article	Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions